arcc 4 negative control

ARCC 4 negative control is a negative control for ARCC 4. Binds androgen receptors (AR) without inducing degradation.

Negative control for TBK1 PROTAC 3i. Binds TBK1 with high affinity, but exhibits no significant degradation of TBK1. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1].

The compound is a negative control peptide for the Bax inhibitor peptides V5 and P5.

siRNA Negative Control, a 21-nucleotide siRNA, serves as a negative control.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

ELA-14 negative control is an inactive peptide that serves as a negative control for ELA-14.

SP 600125, negative control is a methylated analog of SP 600125 and can be used as a negative control for SP 600125. SP 600125, negative control inhibits DTP3 and GADD45β/MKK7 (growth arrest and DNA damage-inducible β/mediator-activated protein kinase kinase kinase 7) and is capable of restoring activation.The IC50s of SP 600125, negative control against JNK2 and JNK3 were 18 and 24 μM, respectively.

ERK Inhibitor II (Negative control) effectively blocks extracellular signal-regulated kinase (ERK) and interferes with insulin receptor activation, serving as a useful tool in diabetes research.